Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

BACKGROUND: Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A candidate vaccine, Ad26.COV2.S, is a recombinant, replication-incompetent adenovirus serotype 26...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Sadoff, Jerald, Le Gars, Mathieu, Shukarev, Georgi, Heerwegh, Dirk, Truyers, Carla, de Groot, Anne M., Stoop, Jeroen, Tete, Sarah, Van Damme, Wim, Leroux-Roels, Isabel, Berghmans, Pieter-Jan, Kimmel, Murray, Van Damme, Pierre, de Hoon, Jan, Smith, William, Stephenson, Kathryn E., De Rosa, Stephen C., Cohen, Kristen W., McElrath, M. Juliana, Cormier, Emmanuel, Scheper, Gert, Barouch, Dan H., Hendriks, Jenny, Struyf, Frank, Douoguih, Macaya, Van Hoof, Johan, Schuitemaker, Hanneke
Formato: Artigo
Idioma:Inglês
Publicado em: Massachusetts Medical Society 2021
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7821985/
https://ncbi.nlm.nih.gov/pubmed/33440088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2034201
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados